|
1
|
American Cancer Society. Cancer Facts and
Figures. 2012, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
Accessed January 23, 2012
|
|
2
|
National Cancer Institute. SEER Stat Fact
Sheets: Breast Cancer Statistics. http://seer.cancer.gov/statfacts/html/breast.html.
Accessed March 6, 2012
|
|
3
|
National Cancer Institute. SEER Stat Fact
Sheets: Corpus and Uterus, NOS. Cancer Statistics. http://seer.cancer.gov/statfacts/html/corp.html.
Accessed March 6, 2012
|
|
4
|
R Development Core Team. R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2011, http://www.r-project.org.
Accessed March 16, 2012
|
|
5
|
Fisher B, Costantino JP, Redmond CK,
Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in
tamoxifen-treated breast cancer patients: findings from the
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J
Natl Cancer Inst. 86:527–537. 1994. View Article : Google Scholar
|
|
6
|
Fisher B, Costantino JP, Wickerham DL,
Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, et al:
Tamoxifen for the prevention of breast cancer: current status of
the National Surgical Adjuvant Breast and Bowel Project P-1 study.
J Natl Cancer Inst. 97:1652–1662. 2005. View Article : Google Scholar
|
|
7
|
Bland AE, Calingaert B, Secord AA, Lee PS,
Valea FA, Berchuck A, Soper JT and Havrilesky L: Relationship
between tamoxifen use and high risk endometrial cancer histologic
types. Gynecol Oncol. 112:150–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferguson SE, Soslow RA, Amsterdam A and
Barakat RR: Comparison of uterine malignancies that develop during
and following tamoxifen therapy. Gynecol Oncol. 101:322–326. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapman JA, Meng D, Shepherd L, Parulekar
W, Ingle JN, Muss HB, Palmer M, Yu C and Goss PE: Competing causes
of death from a randomized trial of extended adjuvant endocrine
therapy for breast cancer. J Natl Cancer Inst. 100:252–260. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bergman L, Beelen ML, Gallee MP, Hollema
H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial
cancer after tamoxifen for breast cancer. Comprehensive Cancer
Centres’ ALERT Group Assessment of Liver and Endometrial cancer
Risk following Tamoxifen. Lancet. 356:881–887. 2000.PubMed/NCBI
|
|
11
|
Saadat M, Truong PT, Kader HA, Speers CH,
Berthelet E, McMurtrie E and Olivotto IA: Outcomes in patients with
primary breast cancer and a subsequent diagnosis of endometrial
cancer: comparison of cohorts treated with and without tamoxifen.
Cancer. 110:31–37. 2007. View Article : Google Scholar
|
|
12
|
Arriagada R, Le MG, Dunant A, Tubiana M
and Contesso G: Twenty-five years of follow-up in patients with
operable breast carcinoma: correlation between clinicopathologic
factors and the risk of death in each 5-year period. Cancer.
106:743–750. 2006.PubMed/NCBI
|
|
13
|
Soerjomataram I, Louwman MW, Ribot JG,
Roukema JA and Coebergh JW: An overview of prognostic factors for
long-term survivors of breast cancer. Breast Cancer Res Treat.
107:309–330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Russo J, Frederick J, Ownby HE, Fine G,
Hussain M, Krickstein HI, Robbins TO and Rosenberg B: Predictors of
recurrence and survival of patients with breast cancer. Am J Clin
Pathol. 88:123–131. 1987.PubMed/NCBI
|
|
15
|
Merrill RM and Dearden KA: How
representative are the surveilance, epidemiology, and end results
(SEER) program cancer data of the United States. Cancer Causes
Control. 15:1027–1034. 2004. View Article : Google Scholar : PubMed/NCBI
|
